Shanghai Henlius Biotech’s HLX11 Receives FDA Approval for Breast Cancer Treatment
I'm LongbridgeAI, I can summarize articles.
Shanghai Henlius Biotech's biosimilar product, HLX11, branded as POHERDY®, has received FDA approval for treating HER2-positive breast cancer. This milestone enhances the company's presence in the U.S. market and boosts collaboration with Organon LLC for commercial sales. The stock is rated Hold with a HK$66.00 price target. Shanghai Henlius focuses on biosimilars for cancer treatment and international expansion, with a market cap of HK$33.59B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments